Alphatec Holdings (ATEC) Company Report

Alphatec (ATEC) reported outstanding Q3 lateral performance and sees significant growth potential in the lateral spine market, aiming to convert traditional posterior approaches with integrated technologies like navigation and Valence robotics.
The company plans to continue its outsized growth rate by expanding its sales force, attracting new surgeons (currently growing at a net rate of 20%), and leveraging new technologies such as the Valence robotics system and the EOS informatics platform for improved surgical decision-making and expanded applications in deformity and cervical surgery.
Alphatec is focused on self-funding its growth by 2026, with a strategy to invest $0.75 in sets and inventory for every $1 of revenue growth, and expects profitability in 2025 to be critical for this goal.
The Valence robotics system is designed with a small footprint and lower cost of goods, allowing for a disruptive placement strategy that avoids long capital cycles and targets both ASCs and small community hospitals.

3 days ago

Transcript

Alphatec Discusses Growth Drivers, Market Opportunities, and Self-Funding Outlook

ATEC

Revenue Acceleration/Inflection

New Projects/Investments

Guidance Update

Alphatec identifies substantial growth opportunities in the lateral spine market, estimated at $1 billion, with an additional $2 billion from traditional posterior approaches that could transition to lateral.
The company is driving growth through technological integration, including Valence (navigation robotics) to reduce radiation and improve predictability, and the EOS informatics platform, which is expected to significantly influence results from 2026-2028.
Alphatec projects absolute dollar growth of just under $150 million year-over-year, supported by a 20% net growth rate in surgeons and a higher average selling price (ASP).
Strategic expansion includes growing its sales force and increasing geographic penetration, aiming to replicate its 20% market share in highly penetrated areas across other regions.
The company anticipates achieving self-funding status by exiting 2025 into 2026, with profitability generating sufficient EBITDA to fund future investments in sets, inventory, and new technologies like Valence without needing to raise additional capital.

3 days ago

Transcript

Alphatec Highlights Strong Lateral Performance and Future Growth Drivers

ATEC

Revenue Acceleration/Inflection

New Projects/Investments

Alphatec (ATEC) reported outstanding lateral performance in Q3, with management indicating significant market expansion potential from the current $1 billion to potentially $2 billion by converting traditional posterior approaches.
Key growth catalysts include the integration of Valence navigation robotics to enhance precision and reduce radiation, expansion into complex pathologies like deformity, and the evolving EOS informatics platform.
The company projects nearly $150 million in absolute year-over-year growth for the current guide and views the Street's $130 million growth estimate for next year as achievable with potential to exceed.
Alphatec aims for self-funded growth by 2026, with a strategy to invest $0.75 in sets and inventory for every $1 of revenue growth, including $120 million invested in 2024 and $40-$50 million planned for 2025.

3 days ago

Transcript

ATEC Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ATEC

Earnings

Guidance Update

Revenue Acceleration/Inflection

ATEC reported Q3 2025 total revenue of $197 million, a 30% increase year-over-year, with surgical revenue growing 31% and EOS revenue up 29%.
Adjusted EBITDA reached $26 million, representing 13% of revenue and an 840 basis point improvement compared to the prior year period.
The company generated $5 million in positive free cash flow for Q3 2025, marking its second consecutive quarter of positive free cash flow and the first time achieving positive free cash flow on a trailing 12-month basis.
Full-year 2025 guidance was raised, with expected total revenue of $760 million (up $18 million) and adjusted EBITDA of $91 million (up $8 million), implying a 12% adjusted EBITDA margin.
ATEC remains confident in achieving its 2027 long-range plan targets of $1 billion in revenue, 18% adjusted EBITDA, and $65 million of free cash flow, with an LRP update expected in late 2026.

Oct 30, 2025, 8:30 PM

Transcript

Alphatec Announces Strong Q3 2025 Results and Raises Full-Year Guidance

ATEC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Alphatec reported Q3 2025 total revenue of $197 million, a 30% increase compared to the prior year period, and an adjusted EBITDA of $26 million, representing 13% of revenue.
The company generated $5 million in positive free cash flow for Q3 2025, marking its second consecutive quarter of positive free cash flow, and its trailing 12-month free cash flow turned positive for the first time in company history.
Alphatec raised its full-year 2025 revenue guidance to $760 million and its adjusted EBITDA guidance to $91 million, which implies a 12% adjusted EBITDA margin for the full year.
Surgical revenue grew 31% year-over-year, driven by 30% same-store sales growth and a 26% increase in net new surgeon users.
The company expects 2026 free cash flow to be in the $20 million range, as it progresses towards its 2027 long-range plan commitment of $65 million in free cash flow.

Oct 30, 2025, 8:30 PM

Transcript

Alphatec Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ATEC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Alphatec (ATEC) reported Q3 2025 total revenue of $197 million, marking a 30% increase compared to the prior year, with surgical revenue growing 31% and EOS revenue up 29%.
The company achieved a record adjusted EBITDA of $26 million, which is 13% of revenue and an 840 basis point improvement year-over-year, alongside $5 million in free cash flow.
ATEC raised its full-year 2025 revenue guidance by $18 million to $760 million and its adjusted EBITDA guidance to $91 million, implying a 12% adjusted EBITDA margin for the year.
Operational strength was demonstrated by 30% growth in U.S. same-store sales and a 26% increase in net new surgeon users.
The company remains focused on its spine-centric proceduralization strategy, with the upcoming full launch of its Valence system and continued progress towards its 2027 long-range plan targets of $1 billion in revenue and $65 million in free cash flow.

Oct 30, 2025, 8:30 PM

Transcript

ATEC Announces Q3 2025 Financial Results

ATEC

Earnings

Revenue Acceleration/Inflection

Guidance Update

ATEC reported total revenue of $197 million in Q3 2025, representing a 30% growth year-over-year.
The company achieved Adjusted EBITDA of $26 million, which is 13% of revenue and reflects an 840 basis points improvement year-over-year.
ATEC posted Non-GAAP Net Income of $4 million for Q3 2025, marking its second consecutive quarter of non-GAAP net income profitability.
The company generated positive free cash flow of $5 million in Q3 2025, making it the second consecutive quarter of positive free cash flow and positive in three of the past four quarters.
As of Q3 2025, ATEC held $216 million in cash and access to cash.

Oct 30, 2025, 8:30 PM

Presentation

Alphatec Holdings, Inc. Reports Q3 2025 Financial Results and Raises Full-Year Guidance

ATEC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Alphatec Holdings, Inc. reported total revenue of $197 million for the third quarter ended September 30, 2025, marking a 30% growth.
For Q3 2025, the company achieved non-GAAP net income of $4 million and Adjusted EBITDA of $26 million, with an Adjusted EBITDA margin of 13%.
Alphatec Holdings, Inc. generated $5 million in free cash flow during the quarter and is free cash flow positive for the trailing twelve months.
The company raised its full-year 2025 total revenue guidance to $760 million (24% growth) and non-GAAP adjusted EBITDA guidance to $91 million.

Oct 30, 2025, 8:23 PM

8-K

Alphatec Holdings Reports Q3 2025 Results and Raises Full-Year Guidance

ATEC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Alphatec Holdings (ATEC) reported $197 million in total revenue for the third quarter of 2025, marking a 30% increase, with surgical revenue growing 31% to $177 million.
For Q3 2025, the company achieved $4 million in non-GAAP net income and $26 million in Adjusted EBITDA, representing a 13% margin.
The company generated $5 million in free cash flow during the quarter and reported 26% growth in net new surgeon users.
Alphatec Holdings raised its full-year 2025 guidance, now expecting total revenue to grow 24% to $760 million (up from $742 million) and non-GAAP adjusted EBITDA of approximately $91 million (up from $83 million).

Oct 30, 2025, 8:05 PM

Press Release

Alphatec Holdings, Inc. Stockholders Approve Share Increase and Equity Plan Amendments

ATEC

Proxy Vote Outcomes

Convertible Preferred Issuance

Executive Compensation

At its Annual Meeting on June 11, 2025, Alphatec Holdings, Inc. stockholders approved an amendment to the Certificate of Incorporation, increasing the total authorized shares of stock from 220,000,000 to 420,000,000, including common stock from 200,000,000 to 400,000,000. This amendment became effective on June 12, 2025.
Stockholders also approved an amendment to the 2016 Equity Incentive Plan, increasing the number of shares available for issuance under the plan to 38,383,333 shares of Common Stock, effective June 11, 2025.
Other approvals at the Annual Meeting included the election of nine directors and the non-binding advisory approval of named executive officer compensation.

Jun 13, 2025, 12:00 AM

8-K

Earnings Transcripts

Quarterly earnings call transcripts for Alphatec Holdings.

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 31, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Patrick S. Miles say about margins?What are Alphatec Holdings's strategic priorities?How is Alphatec Holdings positioned vs competitors?How did Alphatec Holdings do last quarter?

Alphatec Holdings (ATEC)

Analyst Earnings Quarterly Reports

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Executives

Patrick S. Miles

Ali Shorooghi

Craig E. Hunsaker

David P. Sponsel

J. Todd Koning

Joseph Walland

Scott Lish

Tyson Marshall

Board Members

David Demski

David R. Pelizzon

Karen K. McGinnis

Keith Valentine

Mortimer Berkowitz III

Quentin Blackford

Ward W. Woods

Analyst Coverage

David Saxon

Brooks O'Neil

Matthew Miksic

Caitlin Cronin

Eric Anderson

Jason Wittes

Joshua Jennings

Mathew Blackman

Michaela Smith

Vikramjeet Chopra

Xun Lee

Young Li

Andrew Ranieri

Ben Haynor

Kallum Titchmarsh

Matthew O'Brien

Matt Miksic

Phillip Dantoin

Samantha Munoz

Sean Lee

Vik Chopra

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Ask Fintool AI Agent